Study Duration Number of patients Age group TBSA affected (%) LoQ (ng/mL) Pimecrolimus concentration range (ng/mL)
Harper et al. (2001) (61) 3 wks 10* 14-53 months 23-69 0.5 <0.5-1.8
Allen et al. (2003) (62) 3 wks 8** 8-30 months (cohort 2) 28-80 0.5 <0.5-2.0
Allen et al. (2003) (62) 3 wks 8 4-11 months (cohort 3) 25-58 0.1 <0.1-2.6
Lakhanpaul et al. (2002) (63) 49 wks (1-yr extension to Allen et al. (2003) (62) 5 5.7-11.9 months 39-52 0.1 <0.1-1.94
Staab et al. (2005) (65) 3 wks 22 3.4-22.7 months 10-92 0.1 <0.1-2.26
Eichenfield et al. (2007) (64) 3 wks 17 3.6-139.2 months*** 10-48 0.1 <0.1-0.59$